Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

This study has been completed.
Sponsor:
Information provided by:
AmpliMed Corporation
ClinicalTrials.gov Identifier:
NCT00327288
First received: May 17, 2006
Last updated: September 14, 2010
Last verified: September 2010